All In Biotech

Drug Trial Radar · NCT07522099

Chinese Adults With Kidney Disease

A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

Jul 10, 2028

Study completion Jan 21, 2029

Sponsor

Lead sponsor
ADARx Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).

Conditions

  • Immunoglobulin A Nephropathy (IgAN)
  • Complement 3 Glomerulopathy (C3G)
  • IC-MPGN

Interventions

  • ADX-038Drug

    siRNA duplex oligonucleotide

  • TelitaciceptDrug

    fusion protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of ADX-038 as a monotherapy and in combination with telitaciceptTime frame: Part A - 24 Months and Part B - 15 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • ADARx Clinical Site

    Beijing, China · Recruiting

  • ADARx Clinical Site

    Shandong, China · Recruiting

  • ADARx Clinical Site

    Shanghai, China · Recruiting

  • ADARx Clinical Site

    Shenzhen, Guangdong, China · Recruiting

  • ADARx Clinical Site

    Guiyang, Guizhou, China · Recruiting

  • ADARx Clinical Site

    Zhengzhou, Henan, China · Recruiting

  • ADARx Clinical Site

    Baotou, Inner Mongolia, China · Recruiting

  • ADARx Clinical Site

    Wuxi, Jiangsu, China · Recruiting

  • ADARx Clinical Site

    Yantai, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.